Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

TriArm Therapeutics Completes $20 Million Series A Round for Cell Therapies

publication date: Jul 30, 2019

TriArm Therapeutics of Shanghai, Germany and Taiwan completed a $20 million Series A financing to develop next-gen cellular therapies. Founded in 2018, TriArm is developing a CD19 CAR-T product that has a two-to-three-day manufacturing process, which is much shorter than the current three-week process. The A round was led by Panacea Venture, the company's original backer. In December 2018, TriArm formed a $35 million JV, called Eden BioCell, with Boston's Ziopharm for China rights to third-gen CAR-T therapies targeting the CD19 antigen. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here